Rigel Pharmaceuticals, Inc.
RIGL
$32.13
$2.769.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 58.82M | 69.54M | 69.46M | 101.69M | 53.33M |
| Total Other Revenue | -- | 265.00K | -- | -- | -- |
| Total Revenue | 58.82M | 69.80M | 69.46M | 101.69M | 53.33M |
| Cost of Revenue | 16.28M | 16.64M | 12.11M | 11.33M | 12.85M |
| Gross Profit | 42.54M | 53.16M | 57.36M | 90.36M | 40.49M |
| SG&A Expenses | 30.65M | 29.99M | 28.94M | 29.26M | 27.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.93M | 46.63M | 41.04M | 40.58M | 40.56M |
| Operating Income | 11.89M | 23.17M | 28.42M | 61.10M | 12.77M |
| Income Before Tax | 11.66M | 22.71M | 27.62M | 59.98M | 11.51M |
| Income Tax Expenses | 3.00M | -245.35M | -280.00K | 369.00K | 65.00K |
| Earnings from Continuing Operations | 8.65M | 268.07M | 27.90M | 59.61M | 11.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.65M | 268.07M | 27.90M | 59.61M | 11.45M |
| EBIT | 11.89M | 23.17M | 28.42M | 61.10M | 12.77M |
| EBITDA | 12.48M | 23.77M | 29.02M | 61.71M | 13.38M |
| EPS Basic | 0.47 | 14.72 | 1.55 | 3.33 | 0.64 |
| Normalized Basic EPS | 0.40 | 0.78 | 0.96 | 2.10 | 0.40 |
| EPS Diluted | 0.44 | 13.55 | 1.46 | 3.28 | 0.63 |
| Normalized Diluted EPS | 0.37 | 0.72 | 0.90 | 2.06 | 0.40 |
| Average Basic Shares Outstanding | 18.41M | 18.21M | 18.04M | 17.89M | 17.81M |
| Average Diluted Shares Outstanding | 19.69M | 19.79M | 19.16M | 18.16M | 18.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |